!free! — Tni-53

📊 At this stage, TNI-53 has been evaluated primarily in in vitro and early in vivo models. Research indicates dose-dependent reduction of hyperphosphorylated tau and potential improvement in behavioral outcomes in transgenic models. No human clinical trial data are publicly available as of early 2026.

⚠️ TNI-53 is not approved for human use. It remains an investigational tool compound. Any discussion of effects is limited to peer-reviewed preclinical studies. tni-53

#TNI53 #Neuroscience #Tauopathy #AlzheimersResearch #DrugDiscovery 📊 At this stage, TNI-53 has been evaluated